

**BILL SUMMARY**  
1<sup>st</sup> Session of the 52<sup>nd</sup> Legislature

<b>Bill No.:</b>	<b>SB 1119</b>
<b>Version:</b>	<b>CS</b>
<b>Author:</b>	<b>Representative Terrill</b>
	<b>Senator Sykes</b>
<b>Date:</b>	<b>April 21, 2009</b>
<b>Impact:</b>	<b>Annual Net Revenue Increase:</b>
	<b>\$481,000</b>

**Bill Summary**

Research Analyst: Brad Wolgamott

CS for Senate Bill 1119 increases the fees charged by OBNDD for those entities registered to manufacture, distribute, dispense, prescribe or administer controlled dangerous substances. Practitioners registration fee is increased from \$70 to \$140 per year; Home Care Agencies registration fee is increased from \$70 to \$140 per year; Distributors registration fee is increased from \$100 to \$300 per year; Manufacturers registration is increased from \$200 to \$500 per year; Manufacturer, wholesaler or distributor of drugs containing pseudoephedrine or phenylpropalamine is increased from \$100 to \$300. Adds definitions of “recipient” and “recipient’s agent” to definitions used in the Anti-Drug Diversion Act. Modifies the information required for each dispensation of certain drugs to include recipient’s address and date of birth. Requires dispensing information to be transmitted to OBNDD within 24 hours of dispensing.

**Fiscal Summary**

Fiscal Analyst: Marilyn Anderson

SB 1119 increases registration fees for the Bureau of Narcotics and Dangerous Drugs Control’s (OBNDD) prescription monitoring program.

**Fiscal Analysis**

According to the OBNDD, the proposed fee increases would realize approximately \$1,050,000 in annual revenue. At the same time, the agency will be losing a federal grant that helped fund the prescription monitoring program, which costs approximately \$569,000 annually. The remaining \$481,000 in additional revenue from the registration fee increase will help offset increases in general operating expenses.

**Long Term Fiscal Considerations**

None

Fiscal Analysis Reviewed By:

*Janice Buchanan*

House Fiscal Director